Filter
Reset all

Subjects

Content Types

Countries

Data access

Data access restrictions

Database access

Database licenses

Data licenses

Data upload

Enhanced publication

Institution responsibility type

Institution type

Keywords

PID systems

Provider types

Quality management

Repository languages

Software

Repository types

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 3 result(s)
<<<!!!<<< stated 26-02-2020: Amsterdam Cohort Studies on HIV infection and AIDS is no longer available online >>>!!!>>> The Amsterdam cohort study (ACS) on human immunodeficiency virus (HIV) infection and AIDS among homosexual men started in 1984 and was expanded to include drug users in 1985. Thus far, about 2100 homosexual men and 1630 (injecting) drug users have been included of whom approximately 700 homosexual men and 550 drug users are still in active follow-up. Every 3-6 months participants complete a standardized questionnaire to obtain medical, epidemiological and social scientific information and undergo a medical examination. In addition, they have blood drawn for virological and immunological tests and storage.
The Cancer Immunome Database (TCIA) provides results of comprehensive immunogenomic analyses of next generation sequencing data (NGS) data for 20 solid cancers from The Cancer Genome Atlas (TCGA) and other datasource. The Cancer Immunome Atlas (TCIA) was developed and is maintained at the Division of Bioinformatics (ICBI). The database can be queried for the gene expression of specific immune-related gene sets, cellular composition of immune infiltrates (characterized using gene set enrichment analyses and deconvolution), neoantigens and cancer-germline antigens, HLA types, and tumor heterogeneity (estimated from cancer cell fractions). Moreover it provides survival analyses for different types immunological parameters. TCIA will be constantly updated with new data and results.